Exchange: NYSE·Updated 07:30 PM EDT

RDY News

News
all
press releases
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
Zacks
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
Zacks
More News
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
Key PointsSemaglutide supply reloading will begin by November 2026...
Nasdaq News: Markets
Dr Reddy's Laboratories Q2 2027 Earnings Call Transcript
Dr Reddy's Laboratories (NYSE:RDY) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below.This transcript is brought to you byread more...
Benzinga
Top Stock Reports for Oracle, American Express & Progressive
Oracle, American Express and Progressive face contrasting challenges and growth drivers, from underperformance to rising expenses, premium growth and strategic investments.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...
PR Newswire
Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
Dr Reddy's Laboratories (NYSE:RDY) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financialread more...
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...
PR Newswire
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Zacks

Advertisement|Remove ads.